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Pathogenesis of cancer is a multi-step process containing a number of  cellular 
alterations such as post-translational dysregulation of intracellular signaling 
proteins. These alterations control several functions in carcinogenesis such as 
angiogenesis, metastasis, evading growth suppressors, and sustaining prolifera-
tive signaling. Data of various studies has demonstrated that Phosphatidylinositol 
3-kinase (PI3K/AKT) and Mitogen-activated protein kinase (ERK/MAPK) 
pathways are both abnormally activated in many cancer types, including neuro-
blastoma. ERK/MAPK and PI3K/AKT signaling pathways that are regulated by 
sequential phosphorylation upon extracellular stimulation have many important 
functions in cell cycle, migration, proliferation and apoptosis. Besides their aber-
rant phosphorylation/activation, there is a crosstalk between these two pathways 
resulting in an anti-apoptotic effect. In this chapter, carcinogenetic abnormalities in 
post-translational regulation of the activity of ERK/MAPK and PI3K/AKT path-
ways in neuroblastoma and other cancers will be summarized. In addition, several 
crosstalk nodes between two pathways will be briefly explained. All these concepts 
are not only crucial for thoroughly understanding the molecular basis of carcino-
genesis but also choosing the appropriate molecular targets for effective diagnosis 
and treatment.
Keywords: Neuroblastoma, carcinogenesis, intracellular signaling, phosphorylation, 
ERK/MAPK, PI3K/AKT
1. Introduction
Cancer pathogenesis is mainly characterized by the accumulation of genetic, 
epigenetic, and post-translational alterations particularly in cellular signaling 
pathways leading to the manifestation of the cancer hallmarks such as enabling 
replicative immortality, sustaining proliferative signaling, activating invasion and 
metastasis, and inducing angiogenesis. Most of these alterations in the signaling 
pathways are observed on those that control cell growth, proliferation and death, 
cell fate and motility such as ERK/MAPK and PI3K/AKT pathways [1]. Under nor-
mal conditions, cell signaling process works as a regulated cascade, and as a result 
of these regulated signaling, healthy tissue structure is maintained, and cellular 
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functions are properly performed. However, in case of carcinogenesis, a multistep 
progress including various abnormalities in epigenetic and post-translational 
modifications of the components of these signaling pathways (e.g., acetylation, 
methylation, phosphorylation, ubiquitination, sumoylation etc.) occurs that trig-
gers tumorigenic growth [2].
In carcinogenesis, three types of gene groups, oncogenes, tumor-suppressor 
genes, and stability genes are the primary sources for oncogenic mutations. As a 
result of these mutations, genes are over-expressed/silenced, or mutated proteins 
with dysregulated functions are produced. However, examining the carcinogen-
esis in detail revealed that mutated genes are not the only responsible for cancer 
development, and hence focusing on intracellular signaling pathways rather than 
individual genes is more significant. Several mutations may also be observed in 
different components of these signaling pathways, and most of these mutations are 
known to be common for different cancer types [3].
On the other hand, ERK/MAPK and PI3K/AKT signaling pathways have cross 
talking nodes which post-translationally affect their activity and control many of 
the important cellular functions such as cellular metabolism, cell growth, division, 
death, differentiation, and movement. However, this crosstalk becomes severely 
disturbed in many cancers, including neuroblastoma, resulting in rapid disease 
progression and poor prognosis [4–6].
Neuroblastoma is one of the most common pediatric cancers that arises from 
immature sympathetic nervous system precursors and localizes in adrenal gland 
or sympathetic ganglia [7]. Neuroblastoma tumors have a very high degree of 
heterogeneity, ranging from more favorable to highly aggressive tumors with high 
lethality. In neuroblastoma, as in many types of cancer, ERK/MAPK and PI3K/
AKT pathways in particular are notable in terms of their contribution to oncogenic 
transformation and severity of the disease [8, 9].
Therefore, in this chapter, function of ERK/MAPK and PI3K/AKT signaling in 
different cancers, as well as in neuroblastoma will be summarized. Then their aber-
rant and oncogenic interaction with each other and with other cellular components 
will be discussed.
2. ERK/MAPK signaling pathway in cancer
ERK/MAPK is a highly conserved signaling pathway in the evolutionary process 
that provides signal transduction via Receptor Tyrosine Kinases (RTKs). MAPKs 
regulate important cellular functions (e.g., cell cycle, proliferation, migration etc.) 
through phosphorylation of specific serine/threonine regions of target proteins [10, 
11]. Four MAPK cascades have been identified in mammalian cells: Extracellular 
signal-regulated kinase (ERK, classical MAPK), C-Jun N-terminal kinase/stress-
activated protein kinase (JNK/SAPK), p38 MAP kinase, and ERK5 [12]. Among 
them, ERK/MAPK is the most important signaling cascade in tumor development. 
MAPK enzymes in all eukaryotic cells are found at the junctions of mitogenic stimuli 
received by different receptors. In response to received stimuli, the signal is trans-
ferred intracellularly to the small oncogenic G-protein Ras and then to the Raf (MEK 
kinase) protein. Activated Raf protein activates MEK1/2 (MAPK/ERK kinase or 
MAP kinase kinase) signal protein which then phosphorylates and activates ERK1/2 
ultimately regulating essential cellular events such as gene expression, mitosis, cell 
viability, apoptosis, motility, differentiation, and cellular metabolism [13].
In addition to phosphorylation/dephosphorylation, positive and negative regula-
tion of ERK/MAPK signaling involves other types of post-translational modifica-
tions as well. Among them, post-translational modifications of Ras protein such 
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as farnesylation and methylation are intriguing for providing fully active Ras. Ras 
protein activation requires a serial post-translational modifications that allow Ras 
to localize to the plasma membrane [14]. The first post-translational modification is 
farnesylation of the Ras carboxylterminal peptide CAAX through covalent bind-
ing of a farnesyl isoprenoid lipid by cytosolic farnesyltransferase enzyme. Then, 
Ras converting enzyme 1 (Rce1) cleaves AAX tripeptide to generate a free cysteine 
residue. Finally, a methyl group is covalently attached to this cysteine residue by 
isoprenylcysteine-O-carboxyl methyltransferase (ICMT) to facilitate the transfer of 
Ras to the plasma membrane [15].
On the other hand, ERK/MAPK signaling may be downregulated by post-
translational modifications including ubiquitination, SUMOylation, and acetyla-
tion/deacetylation reactions, In a study, it was shown that Ras- or MEK-mediated 
ERK activation is attenuated by SIRT1 through deacetylation of the dual specific 
phosphatase for MAPK, MKP1 which results in the inhibition of cellular prolifera-
tion and transformation. They revealed that binding affinity of deacetylated MKP1 
to ERK is increased subsequently leading to the inactivation of ERK [16].
In addition, ERK1/2 protein may be inactivated by its degradation through 
Ubiquitin-Proteasome System (UPS). This process is mediated by an upstream 
MAP3K, MEKK1 bearing ubiquitin ligase activity, that triggers ERK ubiquitination 
[17, 18]. Another member of ERK/MAPK pathway, c-Raf, is also degraded by the 
UPS under certain conditions. Hsp90 is a chaperone responsible for the stability 
and function of c-Raf protein, and Hsp90 degradation promotes destabilization and 
degradation of c-Raf by UPS. In a study, it was identified that the antitumor effect 
of the antibiotic benzoquinone ansamycin geldanamycin is a result of its binding to 
Hsp90 which triggers its degradation [19].
Fırthermore, the ERK/MAPK signaling may be downregulated by SUMOylation 
of MEK (MAPK–ERK kinase). SUMOylated MEK loses its interacting ability with 
ERK which ends up with the blocking of ERK activation. Oncogenic Ras prevents 
this process in carcinogenesis by disrupting the SUMO E3-ligase activity of MEKK1 
MAPKKK [20].
The ERK/MAPK signaling pathway is one of the main oncogenic pathways and 
overactivated approximately 30% of human tumors [21]. The ERK/MAPK path-
way, particularly when activated by growth factors and mitogens has the strongest 
correlation with cancer. Carcinogenic abnormalities including over-expressing/
activating mutations of RTKs, constant production of activating ligands, and Ras/
Raf mutations trigger the continuous activation of the ERK/MAPK pathway which 
indicates that carcinogenic dysregulation of this pathway may occur at different 
levels (Table 1) [24].
There is a large body of evidence describing the contribution of ERK/MAPK 
signaling to cancer progression. In a study, it was shown that the expression of 
MKP-1 which is the negative nuclear regulator of ERK/MAPK signaling is increased 
in normal ovarian surface epithelium and benign cystadenomas compared to 
invasive carcinomas and tumors with low malignancy potential and borderline 
tumors. The level of MKP-1 expression in tumor tissues of patients with stage III/
IV disease was found to be significantly lower compared to patients with stage I/II 
disease which is in contrast to the results indicating a significantly higher expres-
sion of phosphorylated-ERK1/2 (p-ERK1/2) in stage III/IV tumors compared with 
that in stage I/II tumors. These data point out to a negative correlation between 
MKP-1 and p-ERK1/2 expression in the same ovarian cancer tissue which empha-
sizes the significance of the abnormal expression of MKP-1 and its effect on ERKs 
phosphorylation in the development of ovarian cancer [25].
Moreover, in another study with colon tissue, they showed that in colon cancer, 
tubular adenoma, and villous adenoma, MEK phosphorylation rates were 76, 30 
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and 40%, respectively. However, the phosphorylation of MEK in normal colonic 
mucosal cells was scarcely detectable [26]. In addition, in a study examining ERK/
MAPK pathway’s function in cellular growth and differentiation in colon carcinoma 
of mice by Sebolt-Leopold et al., oral intake of MEK inhibitor provide inhibition of 
tumor growth in the rate of 80% [27].
As in other types of cancer, aberrant signaling of ERK/MAPK pathway is 
crucial for neuroblastoma cancer since it leads to reduced therapeutic efficacy [28]. 
Nevertheless, there is limited number of studies focusing on the role of abnormal 
ERK/MAPK signaling in neuroblastoma cancer. In one study, it was shown that this 
signaling pathway is responsible for the transformation of neuroblastoma cells and 
gaining resistance to chemotherapy [29]. In this study, they incubated SKNSH neu-
roblastoma cell lines with increasing concentrations of doxorubicin or MDL 28842 
for long-term to establish drug resistant SKNSH cell lines. Then they analyzed 
the levels of epidermal growth factor receptor (EGFR) expression and epidermal 
growth factor (EGF)-induced EGFR tyrosine phosphorylation and determined that 
they were both lower in drug-resistant SKNSH cells compared with their wild-type 
counterparts. In addition, in doxorubicin treated SKNSH cells, MAPK activation 
and nuclear translocation were found to be decreased in response to EGF. These 
results reveal that chemotherapeutic drug resistance in human neuroblastoma cell 
lines is in close association with low levels of growth factor signaling through the 
MAPK pathway.
While continuous activation of the ERK/MAPK signaling pathway promote the 
transformation of normal cells into tumor cells, inhibition of the ERK/MAPK signal-
ing can restore tumor cells to their non-transformed state in vivo and in vitro [27]. 
In our laboratory, we examined the effect of ERK/MAPK inhibition on the SH-SY5Y 
neuroblastoma cell viability. Results of MTS cell viability analysis showed that the 
Type of mutations in MAPK signaling pathway Rate of mutations in different cancers
EGFR over-expression Most carcinomas (>50%)
ERBB2 over-expression Breast (30%)
Pancreas (90%)
Lung adenocarcinoma (35%) (non-small cell)
Thyroid; follicular (55%)
Thyroid; undifferentiated papillary (60%)






Acute myelogenous leukemia (30%)
BRAF mutation Melanoma (66%)
Colorectal (12%)
MEK or ERK mutation Melanoma (3–8%)
Colorectal (3%)
Table 1. 
Mutation rates in MAPK signaling pathway of different cancers [22, 23].
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viability of SH-SY5Y neuroblastoma cells upon treatment with the specific MEK1/2 
inhibitor U0126 was significantly decreased. This result indicates a close link between 
ERK/MAPK pathway and carcinogenesis in SH-SY5Y neuroblastoma cells [30].
On the other hand, iron chelators have also been used to inhibit the ERK/MAPK 
signaling pathway and it has been shown in prostate cancer cells that they are able 
to regulate the ERK/MAPK signaling by reducing ERK1/2 phosphorylation [13, 31]. 
Based on the results of these studies, we examined the anti-proliferative effects of 
iron-chelating salicylidene acylhydrazide group synthetic compounds ME0053, 
ME005 and ME0192 in SH-SY5Y neuroblastoma cells by analyzing the effects of 
these compounds on ERK/MAPK and PI3K/AKT activities. The results indicated 
that these iron-chelators caused a significant decrease in MEK1/2 expression and 
AKT phosphorylation in neuroblastoma cells [24]. These results are promising for 
alleviation of the ERK/MAPK activation by utilizing different iron chelators to 
prevent cancer.
Furthermore, current studies have shown that non-steroidal drugs contain-
ing salicylic acid (SA) decrease mortality through mitogenic MEK1/2 protein, an 
important member of ERK/MAPK signaling in many cancers putting a spotlight on 
SA as a potential inhibitor of MEK1/2 signaling in the prevention of carcinogenic 
progression [32–34]. In our laboratory, we studied with a salicylic acid analog 
acibenzolar-S-methyl to analyze its effects on MEK1/2 signaling in SH-SY5Y neuro-
blastoma cells and we showed that acibenzolar-S-methyl negatively affects MEK1/2 
signaling causing apoptotic death of SH-SY5Y neuroblastoma cells [35]. Besides, in 
one study conducted with A549 human lung cancer cells, SA has been demonstrated 
as a suppressor of this vital signaling pathway by inhibiting the binding of c-Raf to 
Ras protein, disrupting phosphorylation state of c-Raf and thereby damaging the 
MAPK signaling [36]. The great number of protein kinases modulated by salicylate 
may be explanatory for the question ‘what is the apoptotic mechanism of salicylate 
in cancer?’ [36, 37].
Moreover, in an effort to suppress ERK/MAPK signaling in neuroblastoma, 
Woodfield et al. [38] hypothesized that inhibiting ERK/MAPK signaling through 
the novel MEK1/2 inhibitor binimetinib may be effective in neuroblastoma mod-
els. For this purpose, they analyzed the response of binimetinib-sensitive and 
binimetinib-resistant neuroblastoma cells from tissue samples and neuroblastoma 
cell lines by examining total and phosphorylated MEK and ERK levels. They 
demonstrated that both primary neuroblastoma tumor cells and cell lines showed 
significant levels of total and phosphorylated MEK and ERK, while binimetinib 
treatment caused complete loss of phosphorylated ERK. However, resistant cells 
showed negligible effects on ERK and MEK phosphorylation. They also showed 
that Ras-GTPase activating protein (RasGAP) NF1 expression was in correlation 
with responses to binimetinib, suggesting a potential role for NF1 and ERK/MAPK 
signaling in neuroblastoma differentiation, drug resistance and relapse [38].
Even though it is well known that ERK/MAPK signaling inhibition results in 
apoptotic death in many cancers, in certain types of cancer such as melanoma, 
suppressing this signal may inversely contribute to cancer formation by creating an 
anti-apoptotic effect [37]. This contradiction draws attention to the heterogeneous 
and unique nature of the molecular basis of cancer emphasizing the vitality of thor-
oughly understanding of molecular and cellular mechanisms of each cancer type.
3. PI3K/AKT signaling pathway in cancer
Similar to the ERK/MAPK pathway, PI3K/AKT signaling pathway is activated by 
the interaction of a growth factor with a RTK that regulates basic cellular functions 
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such as growth, proliferation, cellular metabolism, cytoskeletal organization, 
survival and apoptosis in normal cells [39]. PI3K, is a member of lipid kinase, is 
divided into three classes: classes I, II, and III according to its specific substrates 
and structures. The Class I PI3Ks which are composed of p55 and p85 regulatory 
subunits (p85a, p55a, p50a, p85b, p55g) and p110 catalytic subunit (p110a, p110b, 
p110d) is the most frequently associated class with cancer [40]. In normal cel-
lular conditions, PI3K is activated by growth factors, cytokines, and hormones. 
Following this activation, PI3K triggers the phosphorylation reaction of PtdIns (4,5) 
P2(PIP2) to produce PtdIns (3,4,5) P3(PIP3).
The most important downstream effector protein of PI3K is a serine/threonine 
kinase AKT/protein kinase B (PKB) that regulates several mechanisms in cell 
survival and cell cycle progression [41]. In order to activate AKT signaling, the 
AKT protein is subjected to successive phosphorylation through Thr308 and Ser473 
residues. Semi-active form of AKT protein is achieved by Thr308 phosphorylation, 
while a sequential phosphorylation on Ser473 region at the C-terminal end by PDK2 
(phosphoinositide dependent protein kinase 2) leads to full activation of AKT. 
Activated AKT leaves the membrane and translocates to the cytoplasm and nucleus. 
Here, by phosphorylating a wide range of target proteins such as MDM2, mTOR, 
GSK3β and BAD, it causes cellular responses such as cell proliferation, survival, 
growth, DNA repair and suppression of apoptosis [28].
The negative regulator of the PI3K/AKT signaling pathway is the Phosphatase 
and Tensin homolog protein (PTEN), which has been defined as a tumor suppressor 
and is frequently affected by mutations in cancers. PTEN’s substrate is PIP3, one 
of the PI3K products. PTEN inhibits the PI3K/AKT pathway activity by reducing 
the amount of PIP3, converting PIP3 back to PIP2 via dephosphorylation [42]. 
PTEN stability and activity is post-translationally regulated by Protein Inhibitor 
of Activated STAT xα (PIASxα) which is a SUMO E3 ligase for PTEN. PIASxα 
SUMOylates and stabilizes PTEN protein, thereby negatively regulates PI3K/AKT 
signaling and leads to G0/G1 cell cycle arrest, and cell proliferation inhibition [43].
Moreover, ubiquitination is another way of post-translational regulation of 
PI3K/AKT pathway. p85 subunit of PI3K is ubiquitinated and degraded by trosine-
phosphorylated c-Cbl E3 ligase which ultimately leads to downregulation of PI3K/
AKT signaling [44, 45]. Besides p85 ubiquitination, both caspase- and proteasome-
dependent AKT degradation may downregulate PI3K/AKT signaling in case of 
vascular endothelial growth factor (VEGF) deprivation, mTOR inhibition, or 
TNF-α treatment [46, 47].
AKT signaling controls metabolic processes either directly, by regulating 
metabolic enzymes through phosphorylation, or indirectly, by regulating a number 
of transcription factors. Metabolic enzyme phosphorylation provides short-term 
changes in the metabolic pathways, while controlling gene expression through the 
phosphorylation of transcription factors allows for longer-term changes in intracel-
lular metabolic pathways.
Even though AKT is primarily a survival kinase, it also enhances cell prolifera-
tion. Cyclin D-1 is a cell cycle regulator which is responsible for G1 to S phase 
progression. GSK3β phosphorylates cyclin D-1, enabling its transport from nucleus 
to the cytoplasm for degradation and thereby inhibiting cell cycle. AKT triggers cell 
proliferation not only by inhibiting this GSK3β kinase activity through phosphory-
lation, but also by downregulating cyclin dependent kinase inhibitors KIP1 (p27) 
and CIP1 (p21) [48–50].
Besides cell proliferation, the PI3K/AKT pathway has also been shown to be 
functional in physiologic and pathologic angiogenesis in animal models [51, 52]. In 
tumors, PI3K/AKT pathway exerts its pro-angiogenic effects through upregulating 
HIF-1α, thereby activating VEGF [53]. HIF-1, a heterodimeric protein with α and β 
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subunits, is an activator of VEGF transcription [54]. Moreover, there is data indicat-
ing a HIF-1α-independent pathway for PI3K-mediated VEGF upregulation through 
phosphorylation and activation of endothelial nitric oxide synthase by AKT [55, 56].
Aberrant regulation and activation of the PI3K/AKT pathway is frequent in 
numerous human malignancies playing a pivotal role in both cancer progression 
and drug resistance. PI3K/AKT activation is mainly a consequence of the loss of 
tumor suppressor gene PTEN [57, 58], oncogenic activation of PIK3CA [59, 60] and 
over-activation by a number of growth factors such as IGF-1, VEGF or EGF [61–63].
Loss-of-function mutations in the PTEN gene are extremely common among 
sporadic glioblastomas, melanomas, prostate cancers, and endometrial carcinomas. 
PTEN is negative regulator of the PI3K/AKT signaling pathway that dephosphory-
lates PIP3. Mutated PTEN leads to increased level of PIP3 that trigger continuous 
phosphorylation of AKT, thereby leading to continuous activation of the PI3K/AKT 
signaling pathway. Hyper-activated AKT promotes the survival of cancer cells by 
causing increased level of cell proliferation and resistance to apoptosis [64, 65].
Although it is obvious that PI3K/AKT also contributes to development of 
neuroblastoma, its molecular mechanism is poorly understood. Johnsen et al. [66] 
suggested a link between PI3K/AKT pathway and neuroblastoma through over-
activated AKT which appears to be closely related to the disease outcome. In other 
studies, PI3K/AKT pathway activation was identified as a predictor of poor outcome 
in neuroblastoma, supporting the afore-mentioned study results and making it a 
clinically important therapeutic target [67–69]. In one of these studies, they ana-
lyzed the effect of small molecule PI3K inhibitors on chemosensitivity in neuro-
blastoma cell lines and primary cultured neuroblastoma samples. The results of 
the study showed that PI3K inhibitors, (PI103 for this study), work synergistically 
with certain chemotherapeutics (Doxorubicin, Etoposide, Topotecan, Cisplatin, 
Vincristine and Taxol) to drive neuroblastoma cells through apoptosis. PI103 elicits 
this function by cooperating with chemotherapeutics to decrease the PI3K-mediated 
inhibitory phosphorylation of pro-apoptotic BimEL, thereby turning the situation 
in favor of pro-apoptotic Bcl-2 proteins to trigger apoptosis. Thus, targeting PI3K/
AKT presents a promising strategy to sensitize neuroblastoma cells for chemother-
apy-induced apoptosis [67].
On the other hand, in a study with a murine model of neuroblastoma, they 
showed that inhibiting PI3K/AKT signaling prevents tumor progression through 
an effect on oncogenic Mycn protein stability by inactivating GSK3β [70]. 
Furthermore, AKT phosphorylation has been detected in different neuroblastoma 
cell lines such as SK-N-SH, SH-SY5Y, SK-N-BE, SH-EP, and IMR-32. Studies related 
with neuroblastoma cell lines revealed that activated AKT cause poor prognosis and 
the use of inhibitors specific to the PI3K/AKT signaling pathway leads cancer cells to 
apoptosis [67, 71]. In another study, SH-SY5Y neuroblastoma cells were exposed to 
interferon-β resulting in the downregulation of AKT and subsequent apoptosis [72].
4.  Pathological interaction of ERK/MAPK and PI3K/AKT signaling 
pathways in neuroblastoma
Although the usual signaling networks of hormone, cytokine, and growth factor 
receptors present PI3K/AKT and ERK/MAPK as two independent pathways, there 
are several inter-pathway cross talk nodes as well as certain regulatory molecules 
that can simultaneously act on both pathways which together determine the fate 
of the cell [13, 31]. Based on this information, it can be stated that it is possible for 
the PI3K/AKT and ERK/MAPK pathways to affect each other either negatively or 
positively at different signal propagation stages (Figure 1).
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Examining the mutual talking points of these signaling pathways reveals that 
the activated RAS protein appears to have a binary switch function triggering both 
ERK/MAPK and PI3K/AKT pathways [61, 73]. Another important cross talk is the 
induction of Raf and MEK by PI3K. Cross talk interactions caused by PI3K activa-
tion and mediated by PDK1 activate the ERK/MAPK pathway, while AKT and 
downstream effectors, mTOR and p70S6K, negatively affect ERK/MAPK signaling 
[28]. On the other hand, active ERK can influence the PI3K/AKT pathway in differ-
ent interaction routes. One mechanism involves modulation of the ERK-mediated 
phosphorylation levels at serine and threonine residues of certain AKT members 
(Figure 1) [74]. Moreover, Tuberous Sclerosis Complex 2 (TSC2) can be phosphor-
ylated by either PI3K/AKT pathway or ERK/MAPK pathway, that allows for mTOR 
activation which is a component of PI3K/AKT signaling [75].
Investigating their interaction in terms of carcinogenesis, it is apparent 
that their abnormal interaction has an incontrovertible effect particularly on 
the aggressive progression of different types of cancers. In one of the studies 
examining their interaction in cancer, the role of the ERK/MAPK pathway in 
the control of self-renewal and tumorigenicity of glioblastoma cancer stem-like 
cells (CSLCs) was investigated in relation to the PI3K/AKT pathway. When they 
inactivated MEK1/2 using chemical inhibitors or siRNA, both cell line- and 
patient derived glioblastoma CSLCs were shown to lose their spherical form and 
differentiate into neuronal and glial lineages. Further, this observed effect of 
MEK inactivation was enhanced by using a dual inhibitor (NVP-BEZ235) of PI3K 
and mTOR suggesting that inactivating either ERK/MAPK or PI3K/AKT pathway 
leads to activation of the other, implying the presence of a mutual inhibitory 
cross talk between them [4].
Figure 1. 
Interactions of PI3K/AKT and ERK/MAPK pathways.
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In another study emphasizing the importance of concomitant inhibition of 
both pathways in terms of preventing the contributing effect of their cross talk 
on carcinogenic progression, a mouse model co-expressing the activated forms 
of AKT and Ras in the liver of mouse was utilized. They showed that continu-
ously and simultaneously activated ERK/MAPK and PI3K/AKT signaling causes 
accelerated liver tumor development through activation of mTOR. In order to 
reveal the exact role of mTOR activation in AKT/Ras induced hepatocellular 
carcinoma, they treated AKT/Ras mice with mTOR inhibitor Rapamycin, and 
they found out that Rapamycin significantly prevented tumor formation in the 
liver of AKT/Ras mice. However, Rapamycin withdrawal resulted in rapid recur-
rence of hepatocellular carcinoma arising from the residual lesions in the liver of 
AKT/Ras mice through upregulation of ERK and its downstream effectors, Mnk1 
and eIF4E in the lesions. Simultaneously suppressing PI3K/AKT and ERK/MAPK 
pathways was shown to significantly inhibited the growth of AKT/Ras cells in 
vitro, indicating that there is apparently a sophisticated interaction between these 
two pathways [5].
As in glioblastoma and hepatocarcinoma, cross talk between the PI3K/AKT and 
ERK/MAPK pathways contribute to carcinogenesis in rhabdomyosarcoma which 
is a rare cancer type of soft tissue. Since there is a multifaceted cross talk and a 
reciprocal compensation between them, blocking both pathways concomitantly in 
order to have a synergistic inhibitory effect on rhabdomyosarcoma progression was 
found to be more effective both in vivo and in vitro [6].
Although the effect of their aberrant cross talk is evident in many cancers, 
there is not sufficient number of studies conducted with neuroblastoma cell lines 
or primary neuroblastoma cells to investigate their oncogenic interaction in this 
cancer. On the other hand, ERK/MAPK and PI3K/AKT pathways, in addition to the 
interactions between their different components, can be affected by other proteins 
that are not members of these pathways [21]. However, the effect of these interac-
tions on the emergence of cancer, especially of neuroblastoma, is not yet known. 
At this point, there are data that strengthen the possibility that one of the proteins 
likely to have an effect on PI3K/AKT and ERK/MAPK signaling pathways is the 
Speedy/RINGO protein, which is an unconventional cell cycle regulator and plays a 
very important role in many cancers [76].
Speedy/RINGO binds to its partner Cyclin-dependent kinase 2 (CDK2) and 
controls G1-S phase transition in the cell cycle [73]. In order to elicit this function, 
unlike classical cyclins, Speedy/RINGO does not require phosphorylation, and it is 
also resistant to phosphorylating inhibition by cell cycle inhibitors such as p21Cip1 
and p27Kip1 [24]. Because of these properties, Speedy/RINGO can inhibit apoptosis 
and sustain cancerous cell division by overriding many cell cycle checkpoints [77, 
78]. There are various studies conducted with neuroblastoma and breast cancer 
cells showing the contribution of Speedy/RINGO over-expression together with its 
partner CDK2 to the carcinogenic process [79, 80].
Apart from these studies, Speedy/RINGO protein has also been shown to have an 
interaction with ERK/MAPK signaling pathway in a study investigating the tumor 
formation in breast tissue [81]. In this study, they determined that activating ERK/
MAPK pathway resulted in Speedy/RINGO over-expression, and inhibiting this 
signaling decreased Speedy/RINGO expression. Besides, with another study, it was 
shown that Speedy/RINGO over-expression leads to the increased activity of its 
partner proteins, CDK2 and Cyclin A [82]. On the other hand, studies with mouse 
embryonic stem cell indicated that the Cyclin A2 and CDK2 take part in AKT over-
phosphorylation and activation (Figure 1) [83].
Considering the results of all these studies has led us to raise the question that 
“could there be an either direct or indirect three-way interaction between these 
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three players, Speedy/RINGO, ERK/MAPK and PI3K/AKT pathways in neuro-
blastoma cells?”. To analyze this interaction, Speedy/RINGO gene expression 
was silenced by siRNA in SH-SY5Y neuroblastoma cells in order to determine its 
effect on the activity of ERK/MAPK and PI3K/AKT pathways. Results showed that 
silencing Speedy/RINGO in neuroblastoma cells significantly decreased MEK1/2 
expression in ERK/MAPK pathway, and AKT Thr308 and Ser473 phosphorylations 
in PI3K/AKT pathway. Afterwards, ERK/MAPK signaling was blocked by a specific 
MEK1/2 inhibitor (U0126) in order to examine the effect of ERK/MAPK inhibition 
on Speedy/RINGO expression and PI3K/AKT signaling activity in SH-SY5Y cells. 
As a result, inhibiting ERK/MAPK signaling significantly reduced the expression of 
Speedy/RINGO and its partners CDK2 and Cyclin A as well as AKT phosphoryla-
tion suggesting a reciprocal interaction between Speedy/RINGO and ERK/MAPK 
and PI3K/AKT signaling pathways [30].
As previously mentioned in this chapter, iron homeostasis is in close relation 
with the regulation of ERK/MAPK and PI3K/AKT signaling activity. There are a 
growing number of studies demonstrating the strong effect of iron chelators on 
these two pathways particularly in prostate cancer [13, 31, 84]. Based on the results 
of these studies, we have investigated the effects of iron-chelating salicylidene 
acylhydrazide compounds (ME0053, ME0055 and ME0192) on the ERK/MAPK, 
PI3K/AKT pathways as well as on Speedy/RINGO expression for the reason that 
it is likely to be one of the effectors of these two pathways [24]. In this study, it 
was observed that both MEK1/2 activity and AKT phosphorylation on Thr308 
and Ser473 sites were decreased together with a significant decrease in Speedy/
RINGO expression emphasizing the effect of different metabolic processes such 
as iron homeostasis on the post-translational regulation of the members of these 
two pathways as well as on their interaction with other effector molecules such as 
Speedy/RINGO.
5. Conclusions
ERK/MAPK and PI3K/AKT pathways are very striking in terms of their 
contribution to carcinogenesis in many cancers. In this chapter, we have sum-
marized the function of abnormal ERK/MAPK and PI3K/AKT signaling and 
their cross talk in cancer with an emphasis on neuroblastoma, and discussed 
their provoking action on the onset, progression, and severity of the disease. All 
afore-mentioned studies in this chapter will pave the way for better understand-
ing of the aberrant post-translational regulation of oncogenic ERK/MAPK and 
PI3K/AKT pathways with an ultimate effort for fine-tuning of treatment modali-
ties for cancer.
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